Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Valves01:16

Heart Valves

10.9K
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
10.9K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

388
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
388
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

457
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
457

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Food Supplementation in Patients Hospitalized for Heart Failure: A Randomized Clinical Trial.

JAMA cardiology·2026
Same author

Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.

JACC. Heart failure·2026
Same author

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction.

JAMA cardiology·2026
Same author

Effect of Early Financial Support on Medication Adherence Among Low-Income Patients Following Heart Failure Hospitalization: The FUND-HF Pilot Trial.

Journal of the American College of Cardiology·2026
Same author

Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.

JACC. Heart failure·2026
Same author

Natriuretic Peptide-Based Screening for Heart Failure Among Adults With Diabetes: A Multicenter U.S. Experience.

JACC. Heart failure·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility
07:46

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility

Published on: August 9, 2024

1.2K

Artificial Intelligence in Valvular Heart Disease: Innovations and Future Directions.

Annette Maznyczka1, Rutger-Jan Nuis2, Isaac Shiri3

  • 1Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Electronic address: https://twitter.com/AMaznyczka.

JACC. Cardiovascular Interventions
|October 29, 2025
PubMed
Summary

Artificial intelligence (AI) can enhance valvular heart disease (VHD) management by analyzing complex data for improved diagnosis, personalized treatment, and better patient outcomes. Rigorous validation is crucial for reliable AI integration in clinical practice.

Keywords:
artificial intelligencedigital twinfusion imagingmulti-modality imagingvalvular heart disease

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility
07:46

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility

Published on: August 9, 2024

1.2K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Area of Science:

  • Cardiology
  • Medical Informatics
  • Artificial Intelligence

Background:

  • Valvular heart disease (VHD) management necessitates integrating diverse patient data, which strains human cognitive capacity.
  • The increasing volume and complexity of data in VHD require advanced analytical tools.

Purpose of the Study:

  • To review the applications of artificial intelligence (AI) in managing valvular heart disease (VHD).
  • To explore future directions and challenges of AI integration in VHD clinical practice.

Main Methods:

  • Review of current AI applications, including machine learning and deep learning, in VHD diagnostics and treatment.
  • Discussion of AI's role in risk prediction, procedural guidance, and digital twin technology for personalized medicine.

Main Results:

  • AI algorithms can uncover hidden patterns in routine investigations (ECG, echocardiography, CT) for risk prediction.
  • AI enhances imaging guidance for improved procedural safety and success.
  • Digital twin technology enables case-specific disease modeling and adverse event prediction.

Conclusions:

  • AI offers significant potential to personalize VHD management and improve clinical outcomes.
  • Rigorous multi-center validation, addressing bias, privacy, and transparency, is essential for AI adoption in healthcare.